Mitochondrial therapeutics encompass a diverse set of approaches targeting mitochondrial dysfunction, a central hallmark of neurodegeneration. Mitochondrial defects—including impaired oxidative phosphorylation (OXPHOS), increased reactive oxygen species (ROS), defective mitophagy, and mitochondrial DNA mutations—are implicated in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and other neurodegenerative conditions. This page covers pharmacological agents, gene therapies, and emerging strategies for restoring mitochondrial health. [1]
| Target | Approach | Examples | [2]
|--------|----------|----------| [3]
| OXPHOS enhancement | Electron transport chain modulators | CoQ10, idebenone, MitoQ | [4]
| Antioxidants | ROS scavengers | MitoQ, SkQ1, SS-31 | [5]
| Mitophagy induction | PINK1/PARKIN activators | Rapamycin, urolithin A | [6]
| Mitochondrial dynamics | Fission/fusion modulators | Mdivi-1, SS-31 | [7]
| Mitochondrial biogenesis | PGC-1α activators | Resveratrol, bezafibrate | [8]
| Trial | Agent | Phase | Key Findings | [9]
|-------|-------|-------|--------------| [10]
| NCT00833664 | CoQ10 | Phase 3 | Slowed functional decline in early PD |
| NCT04227067 | MitoQ | Phase 2 | Ongoing |
| NCT04556617 | Urolithin A | Phase 2 | Improves mitochondrial biomarkers |
| NCT05237505 | CoQ10+MCT | Phase 2 | Recruiting |
| Trial | Agent | Phase | Key Findings |
|---|---|---|---|
| NCT03942503 | CoQ10 | Phase 3 | Ongoing |
| NCT04606485 | SS-31 | Phase 2 | Recruiting |
| NCT04449821 | Idebenone | Phase 2 | Mixed results |
| Trial | Agent | Phase | Key Findings |
|---|---|---|---|
| NCT00877386 | CoQ10 | Phase 2 | No significant benefit |
| NCT05160558 | SS-31 | Phase 2 | Ongoing |
| NCT05552434 | Mitochondrial agent | Phase 1 | Safety assessment |
Shults et al. CoQ10 in Parkinson's disease (2002). 2002. ↩︎
Yang et al. MitoQ and mitochondrial function (2020). 2020. ↩︎
Ryu et al. Urolithin A and mitophagy (2016). 2016. ↩︎
Birk et al. SS-31 and mitochondrial function (2013). 2013. ↩︎
Devi et al. Mitochondrial dysfunction in AD (2006). 2006. ↩︎
Schapira & Gegg, Mitochondrial contributions to neurodegeneration (2011). 2011. ↩︎
Lin & Beal, Mitochondrial dysfunction in AD (2006). 2006. ↩︎